• FDA Approves Ocrevus as 1st MS Treatment for Both Relapsing and Primary Progressive Forms
  • Ocrevus’ Journey from Defiant Idea to Game-Changing Treatment
  • The Cluttered Consequences of Multiple Sclerosis Fatigue
  • A Very Hip Story: ‘The Shower That Ate Me’
  • Decisions to Stop Taking Tysabri for MS Are Often Subjective, Study Concludes
  • Canadian Study of MS-Prone Family Proves that in Rare Cases, Multiple Sclerosis is Inherited
  • Canadian Neurologist Traboulsee Reflects on Today’s MS Options
  • Early Use of Tecfidera and Tysabri Improves MS Patients’ Outcomes, Studies Suggest
  • The MS Alphabet: Cytokines, CSF, Corticosteroids and More ‘C’ Words
  • Teva to Discuss MS and Huntington’s Therapies at Premier Neurology Conference
  • AAN Annual Meeting Offers First Ocrevus Data Update Since MS Therapy’s Approval by FDA
  • Season of Spring is Analogous to the Cycles of Chronic Illness
  • A Rap Reply for a Guy Who Thinks MS is Too Perplexin’
  • Getting a Second Opinion: Three Heads — or More — are Better Than Two